Found 5 Presentations For Request "Perdrizet"
CLINICAL AND ECONOMIC BURDEN ATTRIBUTABLE TO SEROTYPES INCLUDED IN FUTURE PNEUMOCOCCAL CONJUGATE VACCINES IN CANADIAN CHILDREN UNDER FIVE YEARS OF AGE (ID 236)
Abstract
Background
In Canada, higher-valence pneumococcal conjugate vaccines (PCV10, PCV13) were introduced into the routine pediatric programs in 2009/2010. Despite their impact, there remains substantial disease burden. PCVs inclusive of up to 20 serotypes (PCV20), currently in development, are expected to considerably expand pneumococcal disease coverage. Our objective was to estimate the clinical and economic burden caused by PCV20 serotypes among Canadian children under five years.
Methods
Epidemiologic, clinical, and cost data were derived or estimated from published sources (Table 1). Cases (invasive pneumococcal disease (IPD), pneumonia, acute otitis media (AOM)), mortality, and direct costs caused by PCV20 serotypes were calculated for children under 5 based on 2017 population figures and assuming IPD serotype distribution for all clinical entities.
Results
Results are summarized in Table 1. Based on our assumptions, PCV20 serotypes were estimated to cover 52% of pneumococcal disease, or a total of 102,036 annual cases. Of these, IPD represented an estimated 0.13%. Total direct attributable costs were 27 million CAD. 
Conclusions
Substantial amount of morbidity from pneumococcal disease, of which IPD represents only a small proportion, could be potentially addressed by the next generation PCVs currently in development.
COST-EFFECTIVENESS AND BUDGET IMPACT OF SWITCHING FROM A LOWER TO A HIGHER VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN BRAZIL (ID 238)
Abstract
Background
Brazil has a 10-valent pneumococcal conjugate vaccine (PCV10) pediatric national immunization program (NIP), even though a 13-valent (PCV13) is available and protects against three additional serotypes, 3, 6A, and 19A. Inadvertently, there has been emergence of PCV10 non-vaccine serotypes, notably 19A. We sought to evaluate the cost-effectiveness and budget impact of switching from PCV10 to PCV13 in 2019.
Methods
The analysis estimated future costs ($BRL), quality-adjusted life years (QALYs), and health outcomes for PCV10 and PCV13 NIPs over five years. The adapted model uses local Brazil serotype and Latin America incidence data from 2009-2018. Input parameters are from Brazilian sources. Future serotype dynamics is predicted using Brazilian and global historical trends (Figure 1).
Results
Over five years, switching from PCV10 to PCV13 prevents 176 thousand disease cases and 20 thousand deaths, gains 29 thousand QALYs, and saves 135 million direct and 3 million indirect costs. After one year, 16 million direct healthcare costs are saved by implementing a PCV13 NIP in Brazil.
Conclusions
Despite a higher PCV13 vaccine cost, a PCV13 NIP is cost-saving compared with PCV10, from both societal and payer perspectives. Brazil should consider switching to prevent disease burden, improve population health, and save immediate healthcare costs.
10-YEAR PUBLIC HEALTH IMPACT FROM 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) IN LATIN AMERICA (ID 240)
Abstract
Background
Pneumococcal conjugate vaccine (PCV) national immunization programs (NIPs) have effectively reduced vaccine serotype pneumococcal disease (PD) morbidity and mortality across Latin America (LatAm). In 2010, the 10-valent and 13-valen PCVs were introduced in routine alimentation. Given PCV13’s broader use and serotype coverage, we quantified its impact across LatAm.
Methods
We calculated the 10-year impact of pediatric PCV13 NIPs in LatAm by estimating PD cases averted and mortality prevented. A model was used to conduct the analysis for ages <5 in 14 LatAm countries that implemented PCV13 NIPs. Data were from reports by the United Nations, World Health Organization, and World Bank for parameters where available. Results are presented by country and aggregately.
Results
Approximately 39.4 million children have been vaccinated. Pediatric PCV13 vaccination translated into 13.7 million total pneumococcal disease cases averted (Table 1). Of the cases averted, 334 thousand were invasive pneumococcal disease, 2.2 million were pneumonia, and 11.2 million were otitis media. Moreover, 49.5 thousand estimated deaths were prevented.
Conclusions
The 10-year history of pediatric PCV13 NIPs in LatAm prevented millions of pneumococcal disease cases and thousands of deaths. However, the true public health impact is underestimated, as herd effects for non-vaccinated groups are not included in the calculations.
CURRENT AND FUTURE PNEUMOCOCCAL CONJUGATE VACCINE SEROTYPE-SPECIFIC BURDEN IN THE UNITED STATES ADULT POPULATION (ID 287)
Abstract
Background
An investigational 20-valent pneumococcal conjugate vaccine (PCV20) is in development and contains the 13 serotypes in PCV13, with 7 additional serotypes 22F,33F,8,10A,11A,12F and 15B. We estimated the epidemiologic and economic burden of pneumococcal disease attributable to serotypes contained in PCV13 and PCV20 for US adults.
Methods
The burden of disease was estimated using published and unpublished data on incidence rates, serotype coverage, mortality, and costs for invasive pneumococcal disease (IPD) and pneumonia. Active Bacterial Core surveillance data from 2017 was used for IPD data. Data was extrapolated to the total US adult population, stratified by age and risk group.
Results
Results are summarized in Table. An additional 9,900 cases of IPD, 44,000 cases of inpatient pneumonia, 52,000 cases of outpatient pneumonia, and 4,300 death are estimated to be caused by the seven new serotypes in PCV20. The new serotypes account for approximately 40% of all cases, deaths, and costs. Direct costs attributed to all PCV20 serotypes are estimated at $4.2 billion.
Conclusions
Pneumococcal disease remains an unmet need in US adults despite increasing uptake with PCV13 and 23-valent polysaccharide vaccine. The seven new serotypes contribute substantially to the clinical and economic burden of pneumococcal disease in adults.
ESTIMATED PNEUMOCOCCAL DISEASE AND ECONOMIC BURDEN FOR CURRENT AND FUTURE VACCINE SEROTYPES IN UNITED STATES IN CHILDREN UNDER FIVE YEARS OF AGE. (ID 288)
Abstract
Background
The 13-valent PCV (PCV13) has reduced vaccine preventable pneumococcal disease caused by serotypes 4,6B,9V,14,18C,19F,23F1,5,7F,3,6A,19A, with cross-protection against 6C. However, non-vaccine type burden remains in the United States (US). Higher-valent PCVs in development will contain additional serotypes 22F,33F,8,10A,11A,12F, and 15B (PCV20). We estimated the remaining clinical and economic burden attributed to current and future vaccine serotypes in US children under five.
Methods
The burden of invasive pneumococcal disease (IPD), pneumonia, and acute otitis media (AOM) was estimated by extrapolating the IPD serotype distribution from 2017 CDC Active Bacterial Core (ABC) surveillance data for PCV13 serotypes (25.0%) and PCV20 serotypes (58.1%) to current population statistics for all clinical entities. Clinical, epidemiologic, and costs data were sourced or estimated from published evidence.
Results
The estimated burden associated with PCV13 and PCV20 serotypes are in Table 1. Based on assumptions, the incremental burden is 700,000 disease cases and 69 deaths annually caused by additional serotypes contained in PCV20. This represented $445 million incremental annual direct costs in 2019 dollars.
Conclusions
Future PCV serotypes encompass a considerable amount of the disease burden. US infant pneumococcal disease and healthcare expenditure may be reduced if future PCVs provide comparable levels of protection as PCV13 serotypes.